Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 6/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8526792 | 0.93 | CSNK2A1 (0.55) | CSNK2A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL10289632 | 0.84 | GPR84 (0.48) | CSNK2A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27447560 | 0.81 | CSNK2A1 (0.50) | CSNK2A1AHRNR4A2CMA1F7 | |
| SCHEMBL8527561 | 0.79 | CSNK2A1 (0.51) | CSNK2A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15984640 | 0.78 | GPR84 (0.47) | CSNK2A1AHRGPR84MAOAMEN1 | |
| SCHEMBL3297032 | 0.78 | GPR84 (0.42) | CSNK2A1AHRNR4A2CMA1F7 | |
| SCHEMBL10289958 | 0.78 | GPR84 (0.62) | CSNK2A1AHRNR4A2CMA1F7 | |
| SCHEMBL613747 | 0.78 | CSNK2A1 (0.69) | CSNK2A1AHRNR4A2CMA1F7 | |
| SCHEMBL14845723 | 0.76 | GPR84 (0.44) | CSNK2A1AHRNR4A2CMA1F7 | |
| SCHEMBL22433008 | 0.75 | TAS1R3 (0.40) | CSNK2A1AHRNR4A2CMA1F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-20150315186-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-05 | — | — | US | disclosed |
| US-20150065487-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150031722-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| US-8802700-B2 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140187770-A9 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140163011-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-12 | — | — | US | disclosed |
| US-8748612-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140155626-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130178496-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2013-07-11 | — | — | US | disclosed |
| US-8367660-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-20130018070-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130011923-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120309758-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
| US-8242149-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-14 | — | — | US | disclosed |
| US-8188283-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100249180-A1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100168158-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-01 | — | — | US | disclosed |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031722-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CSNK2A1 4180/4885GRIN2D 4645/4885GRIN3B 3672/4885 |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | CSNK2A1 3997/4885GRIN2D 4695/4885GRIN3B 3742/4885 |
| US-20100249180-A1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | CFTR, ABCB1, ABCC8 | CSNK2A1 3268/4885GRIN2D 4640/4885GRIN3B 4378/4885 |
| US-20140187770-A9 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CSNK2A1 4180/4885GRIN2D 4645/4885GRIN3B 3672/4885 |
| US-20150065487-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CSNK2A1 4180/4885GRIN2D 4645/4885GRIN3B 3672/4885 |
| US-20120309758-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CSNK2A1 4180/4885GRIN2D 4645/4885GRIN3B 3672/4885 |
| US-20150315186-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CSNK2A1 4180/4885GRIN2D 4645/4885GRIN3B 3672/4885 |
| US-20100168158-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC1 | CSNK2A1 4148/4885GRIN2D 4515/4885GRIN3B 3588/4885 |
| US-20140163011-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CSNK2A1 4180/4885GRIN2D 4645/4885GRIN3B 3672/4885 |
| US-20140155626-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CSNK2A1 3997/4885GRIN2D 4695/4885GRIN3B 3742/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CSNK2A1 1260/4885GRIN2D 326/4885GRIN3B 520/4885 |
| US-20130178496-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC1 | CSNK2A1 4148/4885GRIN2D 4515/4885GRIN3B 3588/4885 |
| US-20130018070-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC1 | CSNK2A1 4148/4885GRIN2D 4515/4885GRIN3B 3588/4885 |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, ABCB1, ABCC1 | CSNK2A1 4148/4885GRIN2D 4515/4885GRIN3B 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.